FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the "Melanoma Research: A bridge from Naples to the World. Napoli, December 5 th-6 th2011"

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Ascierto, Paolo A ^a   Grimaldi, Antonio M ^a   Curti, Brendan ^b   Faries, Mark B ^c   Ferrone, Soldano ^d   Flaherty, Keith ^e   Fox, Bernard A ^f   Gajewski, Thomas F ^g   Gershenwald, Jeffrey E ^h   Gogas, Helen ⁱ   Grossmann, Kenneth ^j   Hauschild, Axel ^k   Hodi, F S ^l   Kefford, Richard ^m   Kirkwood, John M ^d   Leachmann, Sancy ^j   Maio, Michele ⁿ   Marais, Richard ^o   Palmieri, Giuseppe ^p   Morton, Donald L ^c   Ribas, Antoni ^q   Stroncek, David F ^r   Stewart, Rodney ^j   Wang, Ena ^s   Mozzillo, Nicola ^a   Marincola, Franco M ^s   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c SAINT JOHN'S HEALTH CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^j UNIVERSITY OF UTAH   (United States)

^k UNIVERSITY OF KIEL   (Germany)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p CNR   (Italy)

^q UCLA MEDICAL CENTER   (United States)

^r NATIONAL INSTITUTES OF HEALTH   (United States)

^s NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; BLEOMYCIN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR5; CISPLATIN; CXCL9 CHEMOKINE; DABRAFENIB; DACARBAZINE; DENILEUKIN DIFTITOX; DNA; FOTEMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; IPILIMUMAB; STAT1 PROTEIN; STAT3 PROTEIN; SULFORAPHANE; TRAMETINIB; TUMOR NECROSIS FACTOR ALPHA; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ARTICLE; BASAL CELL CARCINOMA; BONE METASTASIS; BREAST CANCER; CANCER GRADING; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG COST; ELECTROCHEMISTRY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; ITALY; KAPOSI SARCOMA; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; ANIMAL; CONFERENCE PAPER; IMMUNOLOGY; MEDICAL RESEARCH; MOUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; HUMANS; IMMUNOTHERAPY; ITALY; MELANOMA; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

EID: 84860342089     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-83     Document Type: Article

References (40)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty P, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459. 10.1200/JCO.2009.27.1627, 2982783, 20368546.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. Melanoma of the skin. AJCC Cancer Staging Manual (ed 7th) 2009, Springer, New York, Edge SE, Byrd DR, Carducci MA.
4. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011, 29:2199-2205. 10.1200/JCO.2010.31.5812, 3107741, 21519009.
5. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol 2010, 17:1475-1477. 10.1245/s10434-010-0986-3, 20300965.
6. Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010, 17:2015-2023. 10.1245/s10434-010-1051-y, 20369298.
7. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011, Dec 16.
8. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010, 17:2006-2014. 10.1245/s10434-010-1050-z, 20379784.
9. Davies MA, Gershenwald JE. Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am 2011, 20:165-180. 10.1016/j.soc.2010.09.003, 3031081, 21111965.
10. Puzanov I, Burnett P, Flaherty KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol 2011, 5:116-123. 10.1016/j.molonc.2011.01.005, 21393075.
11. Curran K, Lister JA, Kunkel GR, Prendergast A, Parichy DM, Raible DW. Interplay between Foxd3 and Mitf regulates cell fate plasticity in the zebrafish neural crest. Dev Biol 2010, 344:107-118. 10.1016/j.ydbio.2010.04.023, 2909359, 20460180.
12. Thomas AJ, Erickson CA. FOXD3 regulates the lineage switch between neural crest-derived glial cells and pigment cells by repressing MITF through a non-canonical mechanism. Development 2009, 136:1849-1858. 10.1242/dev.031989, 2680109, 19403660.
13. Curran K, Raible DW, Lister JA. Foxd3 controls melanophore specification in the zebrafish neural crest by regulation of Mitf. Dev Biol 2009, 332:408-417. 10.1016/j.ydbio.2009.06.010, 2716409, 19527705.
14. Stewart RA, et al. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 2010, 18:750-762. 10.1016/j.devcel.2010.03.009, 3035154, 20493809.
15. Abel EV, Aplin AE. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res 2010, 70:2891-2900. 10.1158/0008-5472.CAN-09-3139, 2848900, 20332228.
16. Katiyar P, Aplin AE. FOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells. Mol Cancer Res. 2011, 9:545-552. 10.1158/1541-7786.MCR-10-0454, 3096755, 21478267.
17. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med. 2012 Mar 15, 10(1):48.
18. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA. CD8+ enriched " young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010 Dec 15, 16(24):6122-6131.
19. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011 Jul 1, 17(13):4550-4557.
20. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011 Mar 1, 29(7):917-924.
21. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human memory T cell subset with stem cell-like properties. Nat Med. 2011 Sep 18, 17(10):1290-1297.
22. Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA. Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment. J Immunother 2012 Apr, 35(3):283-292.
23. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
24. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002, 196:619-628. 10.1084/jem.20012142, 2193999, 12208877.
25. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer treatment reviews 2003, 29:241-252. 10.1016/S0305-7372(03)00074-4, 12927565.
26. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, Hancock B, Lee S, Suciu S, . on behalf of International Malignant Melanoma Collaborative Group Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials [abstract]. Proc Am Soc Clin Oncol 2007, 25(abstr 8526):478S. on behalf of International Malignant Melanoma Collaborative Group.
27. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2010, 102:493-501. 10.1093/jnci/djq009, 20179267.
28. Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson WE, Cohen G, Kirkwood JM. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol 2011, 29(suppl; abstr 8505):5276s.
29. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718. 10.1056/NEJMoa053007, 16481638.
30. Tarhini AA, Edington H, Butterfield LH, Sinha M, Moschos SJ, Tawbi H, Shuai Y, Shipe-Spotloe J, Simonetta M, Milburn C, Horak M, Sander C, Kirkwood JM. Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: Immunogenicity and biomarker analysis. J Clin Oncol 2011, 29(suppl; abstr 8536):534s.
31. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328. 10.1200/JCO.2011.37.5394, 22184371.
32. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534. 10.1200/JCO.2007.12.7837, 18235113.
33. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 20525992.
34. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WA, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T-T, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808.
36. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol 2011, 29(abstr 8519):530s.
37. Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris A, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011, 29(abstr CRA8503):526s.
38. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 2011, 9:196. 10.1186/1479-5876-9-196, 3262765, 22077981.
39. Di Giacomo AM, Ascierto PA, Fonsatti E, Pittiglio E, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Parmiani G, Maio M. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. [2011 ASCO Meeting abstract TPS230]. J Clin Oncol 2011, 29:TPS230.
40. Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, Hollman T, Velazquez E, Russell S, Dipiro P, Yap JT, Van Den Abbeele AD. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011, 29(suppl; abstr 8511):529s.